EXO Biologics, based in Liège, Belgium, develops therapeutics built on exosomes and operates a proprietary ExoPulse production platform. Its lead candidate, EXOB-001 (umbilical cord‑derived MSC exosomes), targets prevention of bronchopulmonary dysplasia (BPD) in preterm newborns and has received Rare Pediatric Disease and Orphan Drug designations from the FDA and ODD from the EMA. The company has launched the EMA‑authorised EVENEW clinical trial for EXOB-001 and is pursuing therapeutic applications across respiratory, inflammatory bowel, neurology, and oncology indications. EXO Biologics also operates ExoXpert, a CDMO leveraging ExoPulse to provide GMP clinical‑grade exosomes for third parties. Future plans include advancing clinical trials, upgrading and expanding the ExoPulse platform, exploring exosomes as delivery vehicles for RNAs, proteins and small molecules, and expanding commercial and manufacturing partnerships. Financially, the company completed a Series A funding package totalling up to €16M to support these development and manufacturing efforts.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024